Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1992 2
1993 2
1994 4
1995 5
1996 2
1997 3
1998 12
1999 5
2000 6
2001 3
2002 6
2003 8
2004 12
2005 6
2006 11
2007 11
2008 15
2009 11
2010 15
2011 9
2012 13
2013 15
2014 13
2015 20
2016 20
2017 13
2018 18
2019 22
2020 12
2021 13
2022 9
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Results by year

Filters applied: . Clear all
Page 1
Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis (ATLAS-PPX).
Kenet G, Nolan B, Zülfikar OB, Antmen B, Kampmann P, Matsushita T, You CW, Vilchevska K, Bagot CN, Sharif A, Peyvandi F, Young G, Negrier CG, Chi J, Kittner B, Sussebach C, Shammas F, Mei B, Andersson SR, Kavakli K. Kenet G, et al. Among authors: negrier cg. Blood. 2024 Mar 7:blood.2023021864. doi: 10.1182/blood.2023021864. Online ahead of print. Blood. 2024. PMID: 38452197 Free article.
Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks.
Kiialainen A, Adamkewicz JI, Petry C, Oldenburg J, Pipe SW, Young G, Mahlangu J, Lehle M, Niggli M, Castaman G, Jiménez-Yuste V, Shima M, Négrier C, Schmitt C. Kiialainen A, et al. Among authors: negrier c. Res Pract Thromb Haemost. 2023 Dec 29;8(1):102306. doi: 10.1016/j.rpth.2023.102306. eCollection 2024 Jan. Res Pract Thromb Haemost. 2023. PMID: 38282901 Free PMC article.
A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.
Pipe S, Sadeghi-Khomami A, Konkle BA, Kitchen S, Negrier C, Liu M, Santagostino E, Willemze A, Abad-Franch L, Knobe K, Seth Chhabra E. Pipe S, et al. Among authors: negrier c. Haemophilia. 2024 Jan;30(1):214-223. doi: 10.1111/hae.14831. Epub 2023 Oct 30. Haemophilia. 2024. PMID: 37902390
Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults.
Konkle BA, Oldenburg J, Pasi J, Kulkarni R, Nolan B, Mahlangu J, Young G, Brown SA, Pabinger I, Shapiro A, Négrier C, Blanchette V, Ragni MV, Dumont J, Lethagen S. Konkle BA, et al. Among authors: negrier c. Res Pract Thromb Haemost. 2023 Aug 22;7(6):102180. doi: 10.1016/j.rpth.2023.102180. eCollection 2023 Aug. Res Pract Thromb Haemost. 2023. PMID: 37753224 Free PMC article.
Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): A multicentric French national observational cross-sectional study based on the FranceCoag registry.
Nguyen NAT, Auquier P, Beltran Anzola A, Harroche A, Castet S, Huguenin Y, Meunier S, Repesse Y, D'Oiron R, Rauch A, Desprez D, Spiegel A, Chamouni P, Schneider P, Baumstarck K, Boucekine M, Tabele C, Viprey M, Leroy T, Roques MA, Sannie T, Giraud N, Chambost H, Resseguier N; TRANSHEMO Study group. Nguyen NAT, et al. Haemophilia. 2023 Sep;29(5):1202-1218. doi: 10.1111/hae.14841. Epub 2023 Aug 12. Haemophilia. 2023. PMID: 37572328
Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.
von Drygalski A, Chowdary P, Kulkarni R, Susen S, Konkle BA, Oldenburg J, Matino D, Klamroth R, Weyand AC, Jimenez-Yuste V, Nogami K, Poloskey S, Winding B, Willemze A, Knobe K; XTEND-1 Trial Group. von Drygalski A, et al. N Engl J Med. 2023 Jan 26;388(4):310-318. doi: 10.1056/NEJMoa2209226. N Engl J Med. 2023. PMID: 36720133 Clinical Trial.
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
Négrier C, Mahlangu J, Lehle M, Chowdary P, Catalani O, Bernardi RJ, Jiménez-Yuste V, Beckermann BM, Schmitt C, Ventriglia G, Windyga J, d'Oiron R, Moorehead P, Koparkar S, Teodoro V, Shapiro AD, Oldenburg J, Hermans C. Négrier C, et al. Lancet Haematol. 2023 Mar;10(3):e168-e177. doi: 10.1016/S2352-3026(22)00377-5. Epub 2023 Jan 27. Lancet Haematol. 2023. PMID: 36716761 Clinical Trial.
287 results